When a prime minister hosts a US president, announcements of trade and security agreements are speculated and expected. What is less usual is a package that puts artificial intelligence and life sciences at its core. The Tech Prosperity Deal, signed during President Trump’s state visit this week, has done just that. The potential for the life sciences sector is huge, especially around the use of AI and quantum technology in the drug discovery process. “Many of the companies we advise are constrained by the time and cost of screening and testing candidates to generate the data required to determine which should be taken forward into pre-clinical and clinical development,” says Kenny Walker-Durrant, a Life Sciences partner at Goodwin. “If AI and quantum technologies can provide management teams with data more quickly and cost-effectively or improve the way that data is interpreted, then they have the potential to accelerate and lower the cost of identifying development candidates.” Read The Lawyer article for more.